1-甲基异喹啉-3-羧酸 | 910123-62-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 1-甲基异喹啉-3-羧酸
• 英文名称: 1-methylisoquinoline-3-carboxylic acid
• CAS: 910123-62-5
• 化学式: C₁₁H₉NO₂
• 分子量: 187.198
• InChiKey: DKZQAXBFQVRGMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  1-甲基异喹啉-3-羧酸 、 6α-naltrexamine dihydrochloride 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以65%的产率得到17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(1-methylisoquinolin-3-carboxamido)morphinan
  参考文献：
  名称：

  Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: Preliminary results on the role of electronic characteristics for affinity and function

  摘要：

  17-Cyclopropylmethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 alpha-(isoquinoline-3'-carboxamido)morphinan (NAQ) was previously designed following the 'message-address' concept and was identified as a potent and highly selective mu opioid receptor (MOR) ligand based on its pharmacological profile. We here report the preliminary structure activity relationship (SAR) studies of this novel lead compound. For the new ligands synthesized as NAQ analogues, their binding assay results showed that a longer spacer and a saturated ring system of the side chain were unfavorable for their MOR selectivity over the kappa and delta opioid receptors. In contrast, substitutions with different electronic properties at either 1'- or 4'-position of the isoquinoline ring of the side chain were generally acceptable for reasonable MOR selectivity. The majority of NAQanalogues retained low efficacy at the MOR compared to NAQin the S-35-GTP[gamma S] binding assays while electron-withdrawing groups at 1'-position of the isoquinoline ring induced higher MOR stimulation than electron-donating groups did. In summary, the electronic characteristics of substituents at 1'- or 4'-position of the isoquinoline ring in NAQ seem to be critical and need to be further tuned up to achieve higher MOR selectivity and lower MOR stimulation. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.07.043
• 作为产物：
  描述：

  methyl 1-methylisoquinoline-3-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以97%的产率得到1-甲基异喹啉-3-羧酸
  参考文献：
  名称：

  Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: Preliminary results on the role of electronic characteristics for affinity and function

  摘要：

  17-Cyclopropylmethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 alpha-(isoquinoline-3'-carboxamido)morphinan (NAQ) was previously designed following the 'message-address' concept and was identified as a potent and highly selective mu opioid receptor (MOR) ligand based on its pharmacological profile. We here report the preliminary structure activity relationship (SAR) studies of this novel lead compound. For the new ligands synthesized as NAQ analogues, their binding assay results showed that a longer spacer and a saturated ring system of the side chain were unfavorable for their MOR selectivity over the kappa and delta opioid receptors. In contrast, substitutions with different electronic properties at either 1'- or 4'-position of the isoquinoline ring of the side chain were generally acceptable for reasonable MOR selectivity. The majority of NAQanalogues retained low efficacy at the MOR compared to NAQin the S-35-GTP[gamma S] binding assays while electron-withdrawing groups at 1'-position of the isoquinoline ring induced higher MOR stimulation than electron-donating groups did. In summary, the electronic characteristics of substituents at 1'- or 4'-position of the isoquinoline ring in NAQ seem to be critical and need to be further tuned up to achieve higher MOR selectivity and lower MOR stimulation. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.07.043

文献信息

• [EN] SUBSTITUTED 3-AMINO-THIENO[2,3-B] PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AS IKK INHIBITORS<br/>[FR] COMPOSES AMIDE D'ACIDE 3-AMINO-THIENO[2,3-B] PYRIDINE-2-CARBOXYLIQUE SUBSTITUE SERVANT D'INHIBITEURS D'IKK
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2005056562A1

  公开（公告）日：2005-06-23

  Disclosed are compounds of formula (I): wherein the variables R1, R2, R3 and Z are described herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

  披露了公式(I)的化合物：其中变量R1、R2、R3和Z如本文所述，它们作为IκB激酶(IKK)复合物的激酶活性的抑制剂是有用的。因此，这些化合物在治疗IKK介导的疾病，包括自身免疫性疾病、炎症性疾病和癌症方面是有用的。还披露了包含这些化合物的药物组合物以及制备这些化合物的方法。
• Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
  申请人：Chen Zhidong

  公开号：US20050182053A1

  公开（公告）日：2005-08-18

  Disclosed are compounds of formula (I): wherein the variables R 1 , R 2 , R 3 and Z are described herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

  本发明公开了式（I）的化合物：其中变量R1，R2，R3和Z如下所述，其可用作IκB激酶（IKK）复合物的激酶活性抑制剂。 因此，这些化合物可用于治疗IKK介导的疾病，包括自身免疫性疾病、炎症性疾病和癌症。 还公开了包含这些化合物的制药组合物和制备这些化合物的过程。
• Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
  申请人：Mjalli M.M. Adnan

  公开号：US20060223849A1

  公开（公告）日：2006-10-05

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及一种抑制β-淀粉样前体蛋白剪切酶（BACE）的苯并咪唑化合物，该化合物可用于治疗或预防BACE参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗BACE参与的这些疾病中使用这些化合物和组合物的用途。
• Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
  申请人：Chen Zhidong

  公开号：US20060270671A1

  公开（公告）日：2006-11-30

  Disclosed are methods of treating cancer by administration of compounds according to formula (I): wherein the variables R 1 , R 2 , R 3 and Z are described herein.

  本发明涉及通过给予式(I)所述化合物治疗癌症的方法：其中变量R1、R2、R3和Z的描述如下。
• Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors
  申请人：Mjalli Adnan M.M.

  公开号：US20090326006A1

  公开（公告）日：2009-12-31

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及抑制β位点淀粉样前体蛋白剪切酶（BACE）的苯并唑化合物，可用于治疗或预防BACE参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的药物组合物，以及在预防或治疗BACE参与的这些疾病中使用这些化合物和组合物的用途。